Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Requires companies to disclose details about drug deals and pharmaceutical transactions.
The problem
The public and regulators lack transparency about how drug companies negotiate prices and make agreements with each other and healthcare providers.
The proposal
The bill mandates pharmaceutical companies disclose specifics of drug deals, including pricing arrangements, discounts, and negotiation details to relevant authorities.
The impact
Drug companies, healthcare providers, insurers, and patients are affected through increased transparency in how medications are priced and distributed.
Disclosure requirements help patients and insurers understand why drug prices are set at certain levels. This transparency can make pricing negotiations fairer and help identify overpriced medications.
Public disclosure of drug deals makes it harder for companies to hide illegal agreements or kickback schemes. Regulators can spot suspicious patterns more easily when information is available.
Patient groups and consumer advocates can use disclosed information to challenge unfair pricing and push for better drug access. This gives ordinary people more power in healthcare decisions.
When companies cannot hide favorable deals from competitors, it may encourage more competitive pricing across the industry. This could lower costs for healthcare systems.
Companies argue that drug deal details include trade secrets and proprietary information they need to keep private. Required disclosure could disadvantage them against international competitors who face fewer restrictions.
Pharmaceutical companies must spend money setting up systems to track and report deal information. These administrative costs could be passed to consumers through higher drug prices.
The bill does not specify exactly what information must be disclosed or how companies should report it. This vagueness could cause confusion and inconsistent compliance across the industry.
U.S. drug companies might lose negotiating power if their deals are publicly known while foreign competitors keep theirs secret. This could harm American pharmaceutical innovation.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.